Hepatitis C virus NS 5 protein

This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in HCV-infected subjects.

本试验目的是参考生物等效性评价方法，研究正大天晴药业集团股份有限公司提供的TQ-A3326片与AstraZenecaPharmaceuticalsLP生产的百立泽TM在健康成年受试者中的生物利用度及药代动力学特点，用以支持TQ-A3326片的注册申报。

评价ASC18片（RDV/SOF复方片）中RDV与SOF的药物相互作用；评价食物对ASC18片药代动力学的影响；比较ASC18片与RDV片和SOF片（RDV+SOF）联用的药动学参数。